

**COMMISSION OF INQUIRY INTO FORENSIC DNA TESTING
IN QUEENSLAND**

Commissions of Inquiry Act 1950

FURTHER SUPPLEMENTARY STATEMENT OF LARA JANE KELLER

I, Lara Jane Keller, of 39 Kessels Road, Coopers Plains, Queensland do solemnly and sincerely declare that:

1. I have previously provided three statements in this Commission of Inquiry dated 9 August 2022, 20 September 2022 and 21 October 2022 (**Supplementary Statement**).
2. Since making my Supplementary Statement, and in preparing to give evidence in this Commission of Inquiry, my memory of certain events has been refreshed by the attached email dated 20 March 2022 (**Exhibit LK-146**).
3. This email shows that on 20 March 2022, I wrote to Professor Keith McNeil, Acting Deputy Director-General (**A/Deputy Director-General**), Prevention Division and Dr Petra Derrington, Chief Pathologist, Pathology Queensland and Forensic and Scientific Services, to inform them that '*... the 2 referrals discussed last week have not been determined to constitute PIDs. Can be managed as part of the review.*'
4. This email has caused me to remember that in relation to the disclosures that I received in March 2022 about the scientific issues which I referred to Queensland Health's Ethical Standards Unit (**ESU**):
 - (a) Prior to 20 March 2022, I did speak with Professor McNeil and Dr Derrington about the two disclosures; and
 - (b) On 20 March 2022, I informed Professor McNeil and Dr Derrington of ESU's decision that the two disclosures did not raise a reasonable suspicion of corrupt conduct pursuant to the *Crime and Corruption Act 2001* and were not public interest disclosures pursuant to the *Public Interest Disclosure Act 2010*.

Lara Jane Keller

Witness

5. Neither Professor McNeil nor Dr Derrington responded to my email. Having said that, I did not expect to receive a response given that the purpose of my email was simply to provide an update on ESU's decision on the referral and confirm that the subject matter of the referral would form part of the External Review.
6. The email also further supports the evidence that I have given in my Supplementary Statement that I intended that the External Review, which I had been actively progressing since mid-February 2022, was to consider the scientific concerns that were the subject of the disclosures that were referred to ESU.
7. I would also like to clarify my evidence in paragraph 72 of my Supplementary Statement, where I say:

... I did not refer the information to the A/Director-General, because of the independence of the ESU's functions, as a matter of practice no other information that is the subject of an ESU referral is referred to the A/Director-General and the confidentiality obligations that I understood applied to me by virtue of section 65 of the PID Act.

8. I wish to clarify that the information that I was referring to in that paragraph was the identity of the disclosers. That is, I would not refer the name of a discloser to the Acting Director-General because of the confidentiality obligations that I understood applied to me. This consideration would not however preclude me from referring the subject of a disclosure to the Acting Director-General. In this case, I referred the scientific concerns that were disclosed to me to the A/Deputy Director-General and Chief Pathologist, Pathology Queensland and FSS.


TAKEN AND DECLARED before me at Brisbane in the State of Queensland this 23rd day of October 2022

Lara Jane Keller

Witness

Schedule of Exhibits

Exhibit	Document title
LK-146	Email 20 March 2022 LK to K McN and PD



Lara Jane Keller

Witness